LoginSignup
immagine del profilo
capital_captain_2693
@capital_captain_2693
1Mes·

Still looking for a share in the pharmaceutical sector?

Just tell us the title and preferably why you find it so interesting.

For your information $CAMX (+0,97%) I already own


Many thanks in advance for all answers

1
32 Commenti
immagine del profilo
Dividendenopi👴@Dividendenopi
1Mes
$NOVO B is currently on special offer 😉😇
•
17
•
immagine del profilo
Tenbagger2024@Tenbagger2024
1Mes
@Dividendenopi Software shares also
•
1
•
immagine del profilo
lukaslr91@lukaslr91
1Mes
@Dividendenopi NOVO has been on sale for more than a year and it is steadily...
••
immagine del profilo
Dividendenopi👴@Dividendenopi
1Mes
@Tenbagger2024 I'm really thinking about whether I should do without dividends for a bit 🤷‍♂️🤔🤔 and look for a few entry points
••
immagine del profilo
Tenbagger2024@Tenbagger2024
1Mes
@Dividendenopi
Good question, which software will survive? AI is already changing things
•
1
•
immagine del profilo
Dividendenopi👴@Dividendenopi
1Mes
@Tenbagger2024 That is a valid objection. We certainly need to reassess some companies. However, AI also brings advantages that are not yet so obvious. Let's run through the current reporting quarter and then sweep up the broken pieces and see what happens next
•
1
•
immagine del profilo
Tenbagger2024@Tenbagger2024
1Mes
@Dividendenopi
Because uncertainty about software will remain on the market.
•
1
•
immagine del profilo
Dividendenopi👴@Dividendenopi
1Mes
@Tenbagger2024 that's the way it is, it could have been different 🤷‍♂️
•
1
•
immagine del profilo
Tenbagger2024@Tenbagger2024
1Mes
@Dividendenopi
Not good for the project right now either 😭
•
1
•
immagine del profilo
Dividendenopi👴@Dividendenopi
1Mes
@Tenbagger2024 jo mei sogt da Bayer. 🙃 You sound a bit pissed off, but you should be above such days.
•
2
•
immagine del profilo
Get_Rich_or_Die_Tryin@Get_Rich_or_Die_Tryin
1Mes
@Dividendenopi lost too much weight too quickly.🤣 Fortunately, the yo-yo effect will probably not happen here.🤷🏼‍♂️
••
Visualizza tutti 11 ulteriori risposte
immagine del profilo
Smudo@Smudeo
1Mes
•
2
•
immagine del profilo
Valesthor@Valesthor
1Mes
$AZN is very broadly positioned in oncology incl. other things listed on the NYSE since yesterday looks very robust good growth.

$HIMS currently has problems with America as generics are being put on hold there to help large companies like Elli Lilly. But is very broadly positioned in telemedicine and online pharmacies. Probably has the greatest growth opportunities but also more risk AstraZeneca is more stable.
•
1
•
investment_wizard_2286@investment_wizard_2286
1Mes
$RVMD is strong in oncology. 2 billion in cash available plus additional funds from a partnership.
Unfortunately I got out before the rocket ignited
•
1
•
Rookie@Rookie
1Mes
$UCB Specialized in neurological diseases.
•
1
•
immagine del profilo
Florian Simon@FloFinance
1Mes
$ABBV has an exciting range of drugs in the fields of immunology and oncology, among others. I estimate that the Group will continue to grow diligently.
•
1
•
immagine del profilo
Max@MaxlvomDach
1Mes
•
1
•
immagine del profilo
core_code@core_code
1Mes
$BNTX through a large oncology pipeline and cash reserves of around EUR 17 billion to finance it
••
immagine del profilo
alphawolf@alphawolf
1Mes
$OMDA could really take off in the coming years thanks to its digitalization and customer growth
••
immagine del profilo
Olli@Olli68
1Mes
My favorite for this year is $SDZ 🚀 🚀 🚀
••
immagine del profilo
PewPewPew@PewPewPew
1Mes
$SDZ the generic market is about to boom
••
Partecipa alla conversazione
IscrivitiAccesso